Hyperfine (HYPR) Cash from Operations Growth (1y) (2022 - 2026)
Hyperfine (HYPR) Cash from Operations Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 129.05 Bn | 126.17 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.63 Bn | 67.18 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.43 Bn | 44.76 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.36 Bn | 27.24 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.14 Bn | 25.85 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.89 Bn | 26.32 Bn | - | - |
| 9 | Koninklijke Philips | 24.25 Bn | 21.12 Bn | 2.07 Bn | 122.43% |
| 10 | Hyperfine | 94.44 Mn | 53.16 Mn | 1.98 Mn | 2.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.61% |
| Dec 31, 2025 | 37.69% |
| Sep 30, 2025 | 34.46% |
| Jun 30, 2025 | 15.70% |
| Mar 31, 2025 | 26.07% |
| Dec 31, 2024 | 15.91% |
| Sep 30, 2024 | 2.34% |
| Jun 30, 2024 | 2.86% |
| Mar 31, 2024 | 7.27% |
| Dec 31, 2023 | 35.24% |
| Sep 30, 2023 | 31.84% |
| Jun 30, 2023 | 42.88% |
| Mar 31, 2023 | 50.56% |
| Dec 31, 2022 | 15.38% |
| Sep 30, 2022 | -28.67% |
| Jun 30, 2022 | -45.56% |
| Mar 31, 2022 | -264.53% |